BRPI0610343B8 - composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo - Google Patents

composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo

Info

Publication number
BRPI0610343B8
BRPI0610343B8 BRPI0610343A BRPI0610343A BRPI0610343B8 BR PI0610343 B8 BRPI0610343 B8 BR PI0610343B8 BR PI0610343 A BRPI0610343 A BR PI0610343A BR PI0610343 A BRPI0610343 A BR PI0610343A BR PI0610343 B8 BRPI0610343 B8 BR PI0610343B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
lower alkyl
morphinan
unsaturated
hydrogen
Prior art date
Application number
BRPI0610343A
Other languages
English (en)
Portuguese (pt)
Inventor
Inagaki Masanao
Haga Nobuhiro
Hara Shin-Ichiro
Hasegawa Tsuyoshi
Goto Yoshihisa
Tamura Yoshinori
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0610343A2 publication Critical patent/BRPI0610343A2/pt
Publication of BRPI0610343B1 publication Critical patent/BRPI0610343B1/pt
Publication of BRPI0610343B8 publication Critical patent/BRPI0610343B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0610343A 2005-05-25 2006-05-25 composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo BRPI0610343B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005-151864 2005-05-25
JP2006065762 2006-03-10
JP2006-065762 2006-03-10
JPPCT/JP2006/310231 2006-05-23
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (3)

Publication Number Publication Date
BRPI0610343A2 BRPI0610343A2 (pt) 2010-06-15
BRPI0610343B1 BRPI0610343B1 (pt) 2020-03-10
BRPI0610343B8 true BRPI0610343B8 (pt) 2021-05-25

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610343A BRPI0610343B8 (pt) 2005-05-25 2006-05-25 composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo

Country Status (19)

Country Link
US (4) USRE46365E1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1889848B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4323547B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100912782B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101228172B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2006250390B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0610343B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2609733C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1889848T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2525215T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR19C1042I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1900034I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007014588A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300996I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1889848T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1889848E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2403255C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI311056B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO2006126529A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2009089494A2 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
CN102159249A (zh) * 2008-09-16 2011-08-17 尼克塔治疗公司 具有低滥用潜在性的聚乙二醇化阿片样物质
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
CN102906099A (zh) * 2010-05-13 2013-01-30 株式会社绿十字 作为神经保护剂的基于(+)-3-羟基吗啡喃的多环衍生物
AU2011327113B9 (en) * 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
JP7076171B2 (ja) 2016-12-26 2022-05-27 塩野義製薬株式会社 含量均一性を改善した製剤の製造方法
AR114489A1 (es) 2018-04-12 2020-09-09 Morphic Therapeutic Inc ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
LT4045039T (lt) 2019-10-16 2025-08-11 Morphic Therapeutic, Inc. Žmogaus integrino alfa4beta7 slopinimas
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) * 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
CA2143864C (en) * 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
CN1090190C (zh) 1996-01-10 2002-09-04 史密丝克莱恩比彻姆股份公司 杂环稠合的吗啡类衍生物,制备方法和用途
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CA2392362A1 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
EP1280529A2 (en) * 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
EP1944292B9 (en) * 2000-10-31 2016-07-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
CN1271072C (zh) * 2001-08-23 2006-08-23 阿克佐诺贝尔公司 14－羟基去吗啡酮衍生物的制备方法
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
KR20050025347A (ko) * 2002-07-11 2005-03-14 도레이 가부시끼가이샤 오심/구토의 치료 또는 예방제
AU2003299045A1 (en) * 2002-09-18 2004-04-08 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
WO2005117589A1 (en) 2004-05-28 2005-12-15 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same

Also Published As

Publication number Publication date
US8536192B2 (en) 2013-09-17
EP1889848B8 (en) 2014-12-17
AU2006250390A1 (en) 2006-11-30
DK1889848T3 (en) 2014-12-01
TW200726470A (en) 2007-07-16
FR19C1042I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-08-09
USRE46365E1 (en) 2017-04-11
CA2609733A1 (en) 2006-11-30
PT1889848E (pt) 2014-12-09
TWI311056B (en) 2009-06-21
RU2007148412A (ru) 2009-06-27
US8084460B2 (en) 2011-12-27
BRPI0610343A2 (pt) 2010-06-15
ES2525215T3 (es) 2014-12-19
AU2006250390B2 (en) 2010-07-08
EP1889848A4 (en) 2011-08-10
US20090203723A1 (en) 2009-08-13
MX2007014588A (es) 2008-01-24
PL1889848T3 (pl) 2015-04-30
WO2006126529A1 (ja) 2006-11-30
WO2006126637A1 (ja) 2006-11-30
BRPI0610343B1 (pt) 2020-03-10
JP4323547B2 (ja) 2009-09-02
NL300996I1 (nl) 2019-07-03
USRE46375E1 (en) 2017-04-25
HUS1900034I1 (hu) 2019-07-29
RU2403255C2 (ru) 2010-11-10
JPWO2006126637A1 (ja) 2008-12-25
CN101228172A (zh) 2008-07-23
NL300996I2 (nl) 2019-07-30
KR20080014791A (ko) 2008-02-14
CA2609733C (en) 2011-07-19
EP1889848A1 (en) 2008-02-20
US20120135978A1 (en) 2012-05-31
FR19C1042I2 (fr) 2020-06-19
KR100912782B1 (ko) 2009-08-18
EP1889848B1 (en) 2014-10-15
CN101228172B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
BRPI0610343B8 (pt) composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
BRPI0517343A (pt) derivados de betulina, preparação destes e uso dos mesmos
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
ATE502939T1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
DE602004022404D1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0413233A (pt) novos compostos
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
UY31736A (es) Derivados sustituidos de pirazol y su uso
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
WO2007103187A3 (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
SG162803A1 (en) Imidazole based lxr modulators
GT200600017A (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion, su uso como medicamento y medicamento que las comprende
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
MX2009008756A (es) Compuesto macrociclico.
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.